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The pathogenesis of Alport syndrome involves type IV collagen mole-
cules containing the a3(IV) chain: Evidence from anti-GBM nephritis
after renal transplantation. Mutations in the COL4A5 collagen gene
have been implicated as the primary defect in Alport syndrome, a
heritable disorder characterized by sensorineural deafness and glomer-
ulonephritis that progresses to end-stage renal failure. In the present
study, the molecular nature of the defect in Alport glomerular basement
membrane (GBM) was explored using anti-GBM alloantibodies (tissue-
bound and circulating) produced in three Alport patients subsequent to
renal transplantation. The alloantibodies bound to the cs3(IV)NC I
domain of type IV collagen and not to any other basement membrane
component. In tissue sections, the alloantibodies bound specifically to
peripheral GBM in normal kidney and the affected renal transplant but
not to that of Alport kidney. These results establish that: the a3 chain
in type IV collagen molecules, the Goodpasture autoantigen, is the
target alloantigen in post-transplant anti-GBM nephritis in patients with
Alport syndrome, and that a molecular commonality exists in the
pathogenesis of anti-GBM nephritis causing loss of renal allografts in
patients with Alport syndrome and renal failure in patients with
Goodpasture syndrome. These findings implicate: (1) defective assem-
bly of type IV collagen molecules containing the a3(IV) chain in Alport
GBM; and (2) the existence of a mechanism linking the assembly of
molecules containing the a3(IV) chain with those containing the a5(IV)
chain.
Alport syndrome is an X-linked heritable disorder that results
in kidney failure and sensorineural deafness [1—31. Clinically,
the nephritis is characterized by hematuria with relentless progres-
sion to end-stage renal disease. The renal lesion is characterized
by ultrastructural abnormalities (thinning, diffuse splitting and
multilaminations of the lamina densa) in the glomerular basement
membrane (GBM). Recent studies indicate that the molecular
defect in Alport GBM is a structural abnormality in type IV
collagen. In normal GBM, type IV collagen is composed of five
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distinct chains, crl(IV) to a5(IV) [4—8]. Mutations of the a5(IV)
gene [9—11], located on X chromosome at the Alport locus Xq22
[8, 12], have been implicated as the primary defect in Alport
GBM. However, the mechanisms through which these mutations
alter the organization of type IV collagen molecules in Alport
GBM remain to be established.
Further insight into the structural nature of the defect in
Alport GBM can potentially be gained by establishing the
specificity of anti-GBM alloantibodies produced in some Alport
patients subsequent to renal transplantation. A fraction of
Alport patients who undergo renal transplantation develop
anti-GBM nephritis causing loss of allograft function. This
phenomenon was first reported a decade ago by McCoy et al
[13], who suggested that normal kidney contains antigens that
are absent in Alport kidney. These observations have been
confirmed by several studies [14-23]. The circulating anti-GBM
antibodies from six Alport patients have now been character-
ized and shown to be directed against the NC 1 domain of type
IV collagen [15, 20—22]. A priori, the recognition of the allo-
graft (normal kidney) as foreign implicates a structural altera-
tion in the type IV collagen molecule in the GBM of the Alport
kidney, that is, an altered organization or absence of one or
more of the five type IV collagen chains. To date, the identity of
these alterations remains unknown.
In the present study, the molecular identity of the target
antigen for anti-GBM alloantibodies from three Alport patients
was determined. These results establish the a3(IV) chain in
type IV collagen molecules as the target alloantigen in the renal
allografts and suggest that defective assembly of molecules
containing the a3(IV) chain occur in Alport GBM.
Methods
Materials
Basement membrane components, type IV collagen domains
and NC1 subunits, and common reagents have been described
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Fig. 1. Binding of AS-I alloantibodies to NC!
hexamer subunits of collagen IV from bovine
GBM by two-dimensional electrophoresis. The
NC! hexamer shown in panel A is stained
with silver and its characteristic features were
described earlier [4]. The p1 markers are
designated by arrowheads. The NCI domain
monomers characterized to date are identified
in the panel. Panel B is the a5(IV) synthetic
peptide antibody staining of NC! hexamer.
The a5(IV)NCI monomer is identified on the
immunoblot. In panel C the binding of
Goodpasture autoantibodies (Patient LL) with
NC! hexamer is shown and the reactive
monomers are identified. In panel D the
binding of AS-I alloantibodies to NC1
hexamer subunits is shown. Immunoblotting
procedure is described in Methods. For
reference a one dimensional gel is shown on
the left side of each panel.
previously [4, 24]. Goodpasture autoantibodies were from pa-
tient LL [4] and Alport alloantibodies were from the patients
described below.
Electrophoresis and ELISA techniques
One- and two-dimensional gel electrophoresis and immuno-
blotting, and ELISA measurements were performed as previ-
ously described [41. The dilutions of antibodies were: Goodpas-
ture autoantibodies 1:50; tissue-bound Alport alloantibodies
(AS-I) 1:1000; circulating Alport alloantibodies (AS-Il and
AS-Ill), 1:640 and 1:320, respectively; and a5(IV)NCI syn-
thetic peptide antibodies 1:200.
Immunofluorescence and immunoelectron microscopy
For immunofluorescence microscopy, bovine and rat kidneys
were snap frozen, and sections of 5 and 4 sm thick, respec-
tively, of the cortex region were sequentially labeled with
Alport alloantibodies diluted to 1:100 with PBS, followed by
incubation with rabbit anti-human IgG-fiuorescein for bovine
tissue sections or with goat anti-human IgG-fluorescein for rat
tissue sections. A 5 sm section of the cortex region of human
kidney was also labeled as mentioned above. To localize
endogenous IgG in the Alport allograft, secondary antibody
incubation of five m tissue section of cortex was performed.
For immunoelectron microscopy, kidneys from ether-anes-
thetized rats were lightly fixed in situ by injection of 2%
paraformaldehyde and 0.1% giutaraldehyde. Wedges of renal
cortical tissue were then frozen and 40 m thick sections were
obtained on a sliding cryostat. Sections were treated with 0.5%
sodium borohydride to reduce residual aldehydes and then
blocked with 0.1% bovine serum albumin in PBS. Sections were
incubated overnight with the Alport antisera or control human
sera (each diluted 1:50 in PBS) and treated for two hours with
horseradish peroxidase (HRP) conjugated goat anti-human IgG,
diluted 1:20 in PBS. Sections were washed, fixed for 10 minutes
with Karnovsky's fixative [25], and developed histochemically
for peroxidase in hydrogen peroxide and diaminobenzidine [26].
Tissue was post-fixed in 2% osmium tetroxide and processed
for electron microscopy.
Case history of Alport patient (AS-I)
A 23-year-old man (AS-I) was admitted to the hospital in 1987
for a living-related renal transplant. A diagnosis of Alport
syndrome was made in 1985 on the basis of the following
observations: (1) the patient had high tone and mid-range
deafness, renal insufficiency, nephrotic-range proteinuria and
microscopic hematuria; and (2) a renal biopsy performed on the
patient's brother revealed mesangial cell hyperplasia, an in-
crease in mesangial matrix, interstitial fibrosis, tubular atrophy
with numerous foam cells, with thinning and splitting of the
basement membrane. The pathology was consistent with famil-
ial nephropathy of Alport's variety.
The first transplant (from the patient's mother) showed signs
of rejection after four months. A transplant renal biopsy dem-
onstrated anti-GBM nephritis. Despite treatment, allograft
function further declined requiring nephrectomy fifteen months
180 Hudson el at: Defect in Alporl GBM
Hudson et a!: Defect in A/port GBM 181
Fig. 2. Identity of NCI dimers which bind
AS-I al/oantibodies by two-dimensional
electrophoresis. Dimers of al(IV)NCI and
a2(IV)NCI (fraction Dl) were resolved from
dimers of a3(IV)NCI, a4(IV)NC1 and
a5(IV)NCI (fraction D2) by HPLC
chromatography as previously described [4].
The pattern of DI and D2 are presented in
panels A and D, respectively, and are
visualized by silver staining as previously
described [4]. Panels B and E show
immunoblotting of Dl and D2, respectively,
with the Alport alloantibodies. Panels C and F
show immunoblots of Dl and, D2
respectively, with GP autoantibodies. The left
side of each panel contains one dimensional
gel for reference. The chain identity of the
numbered components (A and D), and the
identity of those that bound alloantibodies and
GP antibodies are summarized in Table I.
Table 1. Identity of NCI dimers binding Alport alloantibodies and Goodpasture autoantibodies
Antibody binding
HPLC Component Chain identity by Goodpasture Alport
fractions number" Sequence' Immunoblot' autoantibodies alloantibodies
Dl
D2
3, 4, 5, 6, 9 alNCl aINCI — —
10, 11, 12
I, 2,7, 8 a2NC1 a2NCI — —
16,20,21,22 a3NCI a3NCI ++++++ ++++++
13, 14, 15 a4NCl a4NCI + cs3NCl ++ +++
17, 19 a3NCl + aINCI a3NCI + alNCl ++++
18,23 a3NCl+a5NCI a3NCI+a5NCl ++++++ ++++++
24, 25 a3NCl + a5NC1 ++ ++
ab,c,d From reference 4
Immunoblots with Goodpasture autoantibodies and Alport alloantibodies (AS-I, AS-Il and AS-Ill): + weakly intensive and ++++++ strongly
intensive binding.
after transplant. Six months after transplant nephrectomy the 13 of 14 glomeruli wrinkling of the basement membrane, and
patient received a second transplant-six antigen match cadav- patchy, scant lymphocytic interstitial infiltrates. On immuno-
eric kidney. On the tenth post-transplant day, the onset of fluorescence, linear staining of the glomerular capillaries for
hematuria prompted a biopsy which revealed activated infiltrat- IgG and complement was observed. Lucency of the lamina rara
ing cells consistent with acute rejection. A pulse of intravenous interna and fusion of the podocytes was seen by electron
methyiprednisolone was given. A second biopsy of the trans- microscopy. A second diagnosis of anti-GBM nephritis was
plant performed the next day revealed a neutrophilic infiltrate in made. Plasmapheresis was initiated as was the administration of
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hemodialysis was introduced. In 1987, transplantation of a renal
allograft was performed (cadaveric kidney), During the next
five months, renal function rapidly deteriorated. Several renal
biopsies were taken which showed moderate interstitial rejec-
tion. However, end-stage renal failure developed in spite of
intensified immunosuppressive therapy. Histology of the ex-
planted kidney did not suggest rejection, but there was evidence
for glomerulonephritis. One month later, a biopsy of the non-
functioning allograft showed crescentic glomerulonephritis with
linear staining for IgG along the GBM. Circulating anti-GBM
(anti-NC 1-collagen IV) antibodies were demonstrable by
ELISA and Western blotting. Despite an intensified immuno-
suppressive therapy and several plasmapheresis treatments,
renal function could not be re-established and the allograft was
explanted. Circulating anti-GBM antibodies after the second
transplantation were used in the present study.
Case history of A/port patient (AS-Ill)
Fig. 3. Identity of dimers that bind circulating AS-Il and AS-Ill
alloantibodies. Dimers of a3(IV), a4(IV) and a5(IV) were resolved by
HPLC as described previously [4]. The pattern of D2, as visualized by
silver staining, is seen in Figure 2 D. Panel A and panel C are one
dimensional blots of DI and D2 blotted with AS-Il and AS-Ill alloanti-
bodies, respectively. Two dimensional blots are shown in the panels B
and D. The chain identity of NCI components that bound alloantibodies
are summarized in Table I.
high dose prednisone. Cyclophosphamide was substituted for
azathioprine, but there was no reversal of the renal insuffi-
ciency. Dialytic support continued through 12 plasmapheresis
treatments. A follow-up renal biopsy was performed which
revealed crescentic glomerulonephritis, no evidence of acute
rejection, and the presence of linear staining along GBM for lgG
and complement. A transplant nephrectomy was performed and
the tissue bound anti-GBM antibodies were eluted from the
allograft by a procedure described elsewhere [27]. Two weeks
after removal of this second transplant serum, anti-GBM anti-
body measurements were negative.
Case history of A/port patient (AS-Il)
In 1980, a 20-year-old male (AS-I!) with sensorineural deaf-
ness was diagnosed as having microhematuria, proteinuria, and
renal insufficiency, A renal biopsy was taken which showed
typical thinning and splitting of GBM. Based on these findings,
diagnosis of Alport syndrome was established. Within three
years end-stage renal failure developed and chronic intermittent
A nine-year-old male (AS-Ill) was diagnosed with Alport
syndrome upon renal biopsy [28]. The patient showed moderate
sensorineural deafness, microhematuria and subsequent pro-
teinuria. In his 20th year when in terminal renal failure, he
received a renal allograft from his father. Fourteen months
later, deterioration of renal function was observed (serum
creatinine rose from 2.7 to 4.5 mg/dI), plasmapheresis and
immunosuppression was intensified without any effect and
circulating anti-GBM antibodies were positive. Renal biopsy
revealed crescentic glornerulonephritis with positive staining
for IgG along the GBM. In addition, interstitial infiltration,
which is typical for allograft rejection, was observed. For
hemoptysis, the patient did not undergo any specific treatment
and the bleeding stopped after reduction of the body weight by
hemodialysis. During the same period, the patient was diag-
nosed with Fundus albipunctatus (retinal flecks). Circulating
anti-GBM antibodies from this patient were used in the present
study.
Results
Identification of the target alloantigen of GBM
In a recent study [4], we described a procedure, using
two-dimensional electrophoresis in combination with HPLC
chromatography, to resolve and identify the five NC 1 domains
of GBM type IV collagen. This procedure coupled with West-
ern blot analysis provided the requisite knowledge to identify
the a3(IV) chain as the target antigen for Goodpasture autoanti-
bodies [4]. The identical procedure was used herein to deter-
mine the specificity of the anti-GBM alloantibodies.
Eluates of tissue-bound alloantibodies (patient AS-I) were
first analyzed for their capacity to bind NC! hexamer subunits
of type IV collagen from GBM (Fig. 1). For reference, the
electrophoresis pattern for NC I hexamer, visualized by silver
staining, is shown in Figure LA. The antibodies bound princi-
pally to the dimeric subunits (Fig. !D). The one dimensional
pattern (Fig. lD, left side) is very similar to that reported by
others [15, 20—22] for circulating Alport alloantibodies. Except
in the present case, the eluted antibodies bound almost exclu-
sively to dimers. Both one- and two-dimensional patterns for
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Fig. 4. Specfficity of alloantibodies binding to
basement membrane constituents. Symbols
are: (U) control; (0) AS-I; () AS-I!; (0)
AS-ILL. The various basement membrane
components were: F, fibronectin; L, laminin;
HSP, heparan sulfate proteoglycan; CIV,
collagen LV from EHS tumor matrix. The
collagenous domains were from bovine GBM
collagen. The designations are: TH, triple
i— helical domain (pepsin fragments); 7S domain;
NC 1, noncollagenous domain. The monomers
(M) and dimers (D) were from bovine GBM
collagen LV. al(LV)NCI and a2(IV)NCI
dimers comprised fraction Dl, and
a3(IV)NC1, a4(IV)NCI and a5(LV)NC1 were
comprised to fraction D2, as presented in Fig.
2. Fraction D2 is comprised of 73% a3NCl,
8% a4NCl, 10% a5NCl and 9% a1NC1 [4].
dimers are essentially identical to those for Goodpasture anti-
GBM antibodies (Fig. 1D vs. lC), suggesting that the alloanti-
bodies bound principally to cs3(IV)NC1 dimers.
To identify definitively which NC1 dimers bind AS-I alloanti-
body, dimers were first resolved by HPLC chromatography into
fractions Dl and D2, and these fractions were subsequently
resolved by 2D electrophoresis and immunoblotted (Fig. 2). Dl
is composed of crl(IV)NC1 and a2(IV)NC1 dimers, and D2 is
composed of a3(IV)NC 1, a4(IV)NC 1 and a5(IV)NC 1 dimers
along with some monomers. For reference, the patterns for Dl
and D2, visualized by silver staining, are shown in panels A and
D, respectively. The identity of the numbered components was
previously established [4]. AS-I alloantibodies bound to D2
with trace binding to Dl (panels B and E, respectively) analo-
gous to that of Goodpasture antibodies (panels C and F,
respectively). Subunits which bound the alloantibodies, as well
as Goodpasture antibodies correspond to a3(IV)NC1 dimers
(Table 1). Possibly, a5(IV)NC! dimers which occur in very low
quantities in comparison to a3(IV)NC1 dimers, also bound
alloantibodies, but this is equivocal because a5(IV)NC1 dimers
(positions 18, 23-25) comigrate with a3(IV)NC1 dimers (Table
1). Likewise, AS-I alloantibody binding to a5(!V)NC1 mono-
mer is possible on the basis of the immunoblot (Fig. lD), but
this binding is also equivocal because of the comigration of
al (IV)NC 1 and a5(IV)NC 1 monomers. Moreover, the intensity
of this binding is at trace level when compared to total binding
to dimers (Fig. 1D, left side).
The specificity of circulating AS-I! and AS-Ill alloantibodies
for NC1 subunits was also determined (Fig. 3). Again, the 1D
patterns are very similar to those reported by others [15, 20—22].
Moreover, the two-dimensional patterns for dimers were essen-
tially the same as for tissue-bound alloantibodies (vide supra),
indicating that they are targeted to a3(IV)NC1 dimers. Also, the
two-dimensional immunoblots of NC 1 hexamer for AS-Il and
AS-Ill are identical to the patterns shown in Figure 3 for D2
(data not shown). In the case of the circulating alloantibodies,
the binding to monomers was exclusively to a3(IV)NC1.
The specificity of alloantibodies from all three patients for
type IV collagen and other basement membrane components
was also evaluated by ELISA measurements (Fig. 4). The
binding to GBM type IV collagen was restricted to the NC!
domain and specifically to monomers and dimers of a3(IV)NC1.
The binding to a5(IV)NC 1 could not be determined because of
the unavailability of purified a5(IV)NC1. There was essentially
no binding of antibodies to either fibronectin, laminin, heparan
sulfate proteoglycan, entactin, or EHS type IV collagen which
lacks the a3(IV), a4(IV) and a5(IV) chains [29].
Localization of AS-I alloantibody binding to renal tissue
The affected renal allograft of patient AS-I was analyzed by
light microscopy to localize the binding of endogenous IgG.
Linear binding of the alloantibodies to GBM was observed with
no binding to the mesangial matrix (Fig. 5). The binding of
eluted AS-I alloantibody to renal cortex tissue was investigated
for rat, human and bovine kidney (Fig. 5 B, C and D). Linear
binding of alloantibody to GBM was observed in each case and
to some extent to TBM. However, there was no binding to
mesangial matrix in all the cases.
Previous reports have shown that circulating Alport alloanti-
bodies do not bind to GBM of natural kidney of Alport patients
[13, 22]. This phenomenon was further examined with AS-I
alloantibodies. As shown in Figure 6, the alloantibodies bound
to control human GBM and to GBM of a patient with "thin
GBM disease," but not to GBM of a patient with Alport
syndrome. These observations further support the contention
that the target alloantigen is absent or the epitope is masked in
Alport GBM.
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Fig. 5. Immunofluorescence photomicrograph showing localization ofAS-I alloantibodies to the kidney. The endogenous IgG binding to the GBM
of the AS-I renal allograft is shown in the panel A. Panels B, C and D show the linear binding of the eluted AS-I alloantibody to the GBM and to
some extent the TBM in the rat, human and bovine kidney sections (x 595), respectively. There is no mesangial matrix staining observed in all
the cases. The immunofluorescence staining was performed as described in the Methods section.
At the ultrastructural level, the localization of AS-I alloanti-
body binding was determined by immunoelectron microscopy
(Fig. 7). Binding was distributed throughout the peripheral loop
of GBM as well as that part of the GBM that reflected over
mesangial matrices (Fig. 7A). In addition, the alloantibody
bound to biosynthetic organelles within podocytes (Fig. 7B).
There was no binding observed with control human sera (data
not shown). These results indicated that the target antigen for
AS-I alloantibody is primarily localized to peripheral GBM and
not to mesangial matrix.
Discussion
Previous studies have documented that circulating anti-GBM
alloantibodies from transplanted Alport patients bind to the
NC! domain of type IV collagen [15, 20—22]. However, as the
type IV collagen molecules in the GBM are composed of five
distinct chains [al(IV) to a5(IV)] in various combinations, the
identity of the respective NC! domain targeted by the alloanti-
bodies remains unresolved.
In the present study, we used tissue-bound and circulating
antibodies from three Alport patients to identify the target
alloantigen. The a!loantibodies bound to the NC 1 domain of the
a3(IV) chain of type IV collagen. The binding was primarily to
a3(IV)NC1 dimers with some binding to a3(IV)NCI monomers.
The possible binding to a5(IV)NCI dimers could not be ex-
cluded as they comigrate with certain isoforms of cx3(IV)NCI
dimers in the two-dimensional electrophoretic pattern. How-
ever, binding to aS(IV)NC1 monomers, which resolve from
cx3(IV)NC 1 monomers, did not occur using antibodies from two
patients, a finding which provides indirect evidence that ex-
cludes a5(IV)NC1 as the target. Moreover, the alloantibodies
from all three patients bound to a3(IV)NC1 and not to other
domains of type IV collagen or to any other basement mem-
brane constituents. Thus, we conclude that the a3(IV) chain in
type IV collagen molecules is the target Alport alloantigen and
that the epitope(s) resides in the NC! domain of this chain.
The production of these alloantibodies provides an insight
into the molecular organization of type IV collagen in the
defective Alport GBM. In the Alport patient, the normal renal
allograft serves as both the immunogen and the target for the
antibodies, indicating that the patient was not self-tolerant to
the a3(IV) collagen chain. In the allograft, the antibodies bound
to peripheral GBM and not to mesangial matrix. A similar result
was obtained when eluates of the antibody were added to tissue
sections of normal kidney. This localization of binding indicates
that within the glomerulus the distribution of the a3(IV) chain is
restricted to GBM.' In contrast, the alloantibodies did not bind
l This finding corroborates that of others who found a restricted
distribution of the u3 chain with the use of monoclonal antibodies [23,
30].
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Fig. 6. immunofluorescence analysis of AS-I alloantibody binding to
the control and abnormal human GBM. The binding of AS-I alloanti-
bodies to control human GBM (A) and to GBM of "thin BM disease"
(B). No binding of AS-I alloantibodies to Alport GBM was observed
(C).
to GBM of an Alport kidney. Thus, the production of the
anti-a3(IV) chain alloantibody is consistent with the concept
that an alteration in type IV collagen occurs in Alport GBM, in
which the incorporation of molecules containing the a3(IV)
chain is defective, that is, either the chain is absent or an
epitope within the NC1 is altered or masked.
These findings add a third line of evidence for the involve-
ment of the a3(IV) chain in the abnormality of Alport GBM.
First, the binding of Goodpasture autoantibodies to Alport
GBM is frequently absent [13, 16—20] and the binding of a
monoclonal antibody directed against the Goodpasture antigen
in the GBM is absent or diminished in several Alport patients,
as determined by immunofluorescence of tissue sections [21,
23]. Second, a collagenase-resistant component, M28+++,
which corresponds to a3(IV)NC1 monomer, is absent from the
GBM of three Alport patients, based on chemical and immuno-
chemical evidence [31—33]. Third, the alloantibodies from six
Alport patients are targeted to the NC 1 domain of type IV
collagen [15, 20—22], three of which were shown herein to be
targeted to the cr3(IV) chain, and the antibodies do not bind to
Alport GBM. The recent identification of the Goodpasture
antigen as the a3(IV) collagen chain [4, 34, 35] and its existence
in bovine [4, 24] and human GBM [33, 36], together with these
three independent lines of evidence, strongly indicate the
absence of molecules containing the a3(IV) chain in Alport
GBM.
The absence of such molecules in Alport GBM implicates the
existence of a mechanism linking the assembly of type IV
collagen molecules containing the a3(IV) chain with those
containing the a5(IV) chain. The a3(IV) gene is located on
chromosome 2 [35], whereas Alport syndrome is an X-Iinked
disorder involving mutations in the COL4A5 gene [9—11],
encoding the a5(IV) chain and located on X-chromosome Xq22
[8, 12] at the Alport locus [37—39]. Hence, mutations in the
a3(IV) gene cannot account for the primary defect. Therefore,
as postulated by Morrison et al [35], mutations in the a5(IV)
chain lead to a failure in incorporation of the a3(IV) chain into
type IV collagen molecules in the Alport GBM. The evidence
reported herein for the absence of the a3(IV) chain in Alport
syndrome further supports this postulate.
The mechanism linking incorporation of molecules containing
a3(IV) chains with those containing a5(IV) chains may occur at
the protein or at the translational/transcriptional level. At the
protein level, the a3(IV) and a5(IV) chains may normally
interact to form heterotrimers (triple-helical), which in turn,
associate to form a supramolecular structure. Hence, mutations
in the a5(IV) chain could prevent heterotrimer formation or
cause assembly of a defective heterotrimer, resulting in failure
of a3(IV) chain incorporation into GBM. This phenomenon
occurs in osteogenesis imperfecta in which mutations in the
cil(I) chain of type I collagen cause assembly of a defective
heterotrimer composed of [al(I)]2 a2(I) [40]. However, defects
in heterotrimer formation by itself cannot explain the absence
of the a3(IV) chain because the ratio of a3(IV) chains to a5(IV)
chains is about 7:1 in GBM [4], and a value of 2:1 would be
required. Alternatively, a5(IV)-containing trimers that do not
contain the a3(IV) chain may be required for the incorporation
of several a3(IV)-containing trimers. Therefore, the absence or
a defective có(IV)-containing trimer could interfere with the
incorporation of a3(IV)-containing trimers into GBM. At the
translational/transcriptional level, the a5(IV) chain may influ-
ence the expression of the a3(IV) chain. Possibly, transcription
of a3(IV) and a5(IV) chains is regulated by a common factor
encoded by a gene on the X chromosome. Hence, mutations in
this regulatory gene could lead to the altered type IV collagen
composition in Alport syndrome. Ultimately, understanding the
mechanism linking incorporation of molecules containing the
a3(IV) chain with those containing the a5(IV) chain into GBM
may provide fundamental information about the assembly of
basement membrane collagen.
'v-it-Po
)MM- CL
B
—
•
t CL
Fig. 7. Electron micrograph of section of a
portion of rat glomerulus labeled with AS-I
alloantibody. Anti-human IgG-HRP staining is
described in the Methods section. A. Electron-
dense HRP reaction product is seen
throughout the GBM (arrows) and GBM
reflecting over mesangial waist areas
(arrowheads). However, mesangial matrices
(MM) do not contain HRP reaction product.
Abbreviations are: CL, capillary lumen; En,
endothelium; Me, mesangium; Po, podocytes.(x 16,000) B. Electron micrograph from renal
tissue processed as in panel A, showing the
binding of alloantibody to peripheral loop
GBM (arrows) and also intracellularly
(arrowheads) within podocytes (P0). There
was no binding of anti-human IgG-HRP seen
in section processed with control human sera
(data not shown). Abbreviations are: CL,
capillary lumen; US, urinary space. x 15,000.
Finally, the findings reported herein also establish the Alport
alloantigen to be identical to the Goodpasture autoantigen, the
a3(IV) chain. The singularity of the antigen and its occurrence
within the GBM establish a molecular commonality in the
pathogenesis of anti-GBM nephritis causing loss of renal al-
lograft function in patients with Alport syndrome and renal
failure in patients with Goodpasture syndrome. Thus, the
pathogenic anti-GBM antibody in Alport syndrome is desig-
nated anti-a3(IV) collagen antibody, as was designated previ-
ously for Goodpasture syndrome [4, 7].
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